Daniel Fuster, MD, PhD

Dr. Fuster is a postdoctoral fellow who began his training in the CARE Unit in July 2011.  He completed his residency in Internal Medicine at Hospital Universitari Germans Trias i Pujol (Badalona) in Spain.  His research interests are medical consequences of substance abuse, mainly HCV and HIV infection, as well as alcohol abuse. He has obtained a postdoctoral grant from the Spanish Ministry of Education.

Medical School:

MD. Universitat de Barcelona, Spain.

PhD (Cum Laude). Universitat Autonoma de Barcelona, Spain.

PhD dissertation thesis: “Treatment of Chronic Hepatitis C Virus infection in HIV co-infected patients”.

Additional Pre-Fellowship Training and Experience:

Clinical Investigator/Pre-doctoral Fellow. HIV/AIDS Unit. Department of Internal Medicine. Hospital Universitari Germans Trias i Pujol. Badalona.

Post-Doctoral Fellow. Addiction Unit/ Department of Internal Medicine. Hospital Universitari Germans Trias i Pujol. Badalona. 

Attending Physician. Department of Internal Medicine. Hospital Universitari Germans Trias i Pujol. Badalona. Spain.

Member of the Catalonian Royal Academy of Medicine. Barcelona.

Member of the ASMI study group (Alcohol abuse in admitted patients in Internal Medicine Services in Spain). Spanish Society of Internal Medicine.

Pre-Fellowship Related Publications:

D. Fuster, J. Tor, C. Rey-Joly, R. Muga. Pathogenic interactions between alcohol and hepatitis C. Med Clin (Barc). 2011. doi: 10.1016/j.medcli.2011.04.019. [in press].

D. Fuster, R. Planas, J. Gonzalez, L. Force, M. Cervantes, J. Vilaro et al. Results of a study of prolonging treatment with pegylated interferon-alpha 2b plus ribavirin in HIV/HCV coinfected patients with no early virological response. Antivir Ther. 2006; 11: 473-482.

D. Fuster, J.A. Huertas, G. Gomez, R. Sola, J Gonzalez García, J. Vilaro, E Pedrol et al  al for the PEG-TOX Research Group. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. Antivir Ther. 2005;10: 841-847.

D. Fuster, B. Clotet. Review of atazanavir: a novel HIV protease inhibitor. Expert Opin Pharmacother. 2005; 6(9): 1565-1572.

D. Fuster, R. Planas, R. Muga, A.L. Ballesteros, J. Santos, J. Toret al. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses. 2004; 20: 1293-1297.

D. Fuster, B. Clotet. Chronic HCV infection in HIV- positive patients: A new challenge. JIAPAC, 2003; 2 (2): 56- 58.


Spanish Ministry of Education postdoctoral grant 2011.

PhD Thesis Dissertation Award. Catalonian Royal Academy of Medicine. Barcelona. 2007

Best Poster Communication at the XIV Catalan Meeting of Digestive Medicine 2005.

Fellowship Research Projects:

Estimation of liver fibrosis in the HIV-LIVE cohort. Relation with alcohol abuse. Impact on mortality.

Low bone mineral density in patients receiving methadone. Association with laboratory abnormalities. Impact on bone fracture risk.

Mentor: Jeffrey H. Samet MD, MA, MPH

Current Positions: Post-Doctoral Research Scholar. Clinical Addiction Research and Education (CARE) Unit, General Internal Medicine Service. Boston University Medical School/ Boston Medical Center. Boston, MA.